Solvay Group holds 93.1% of Innogenetics shares

Offer on Innogenetics shares is extended from 22 October to 12 November

20-Oct-2008 - Solvay Pharmaceuticals S.A., a subsidiary of the Solvay Group announced that it will acquire 2,714,371 additional shares of Innogenetics N.V. in a cash transaction valued at EUR 6.5 per share, representing EUR 200.7 million for 100% of the Innogenetics shares. The shares were offered to Solvay ...

Solvay Pharmaceuticals acquires Innogenetics

Solvay Group holds 84.3% of Innogenetics shares

11-Sep-2008 - Solvay Pharmaceuticals S.A., a subsidiary of the Solvay Group, announced that it succeeded to acquire Innogenetics N.V. in a cash transaction valued at EUR 6.5 per share, representing EUR 200.7 million for 100% of the Innogenetics shares. The offer on Innogenetics shares ran from 12 August to 5 ...

Solvay Pharmaceuticals S.A. launches friendly bid to acquire Innogenetics

Building on a successful R&D co-operation

29-Apr-2008 - Solvay Pharmaceuticals S.A., a subsidiary of Solvay, and Innogenetics N.V. jointly announced that Solvay Pharmaceuticals S.A. will make a conditional tender offer to acquire Innogenetics in a cash transaction valued at EUR 5.75 per share. Solvay initially entered into an R&D co-operation with ...

Innogenetics announces the intention to restructure its subsidiary GENimmune

14-Feb-2008 - Last year, Innogenetics decided to focus on the development and sales of diagnostic products, and GENimmune N.V. was incorporated as a fully owned subsidiary. GENimmune obtained assets of Innogenetics in the field of drug development. The strategy of Innogenetics is to focus solely on ...

Innogenetics concludes settlement and licensing agreement in the field of Hepatitis C diagnostics

19-Oct-2007 - Innogenetics announced an agreement with Novartis on major licensing terms in the field of Hepatitis C Virus (HCV) diagnostics. According to the license agreement, Novartis grants Innogenetics a license to its Hepatitis C patent rights in the field of HCV immunodiagnostics in certain territories. ...

Innogenetics and Bio-Rad enter into a non-exclusive licensing agreement for HIV-2 patents

26-Feb-2007 - Innogenetics and Bio-Rad Laboratories, Inc. announced that the two companies have finalized a non-exclusive licensing agreement for patents in the field of viral diagnostics. According to the terms of the non-exclusive agreement, Innogenetics will get a license from Bio-Rad that has exclusive ...

Sanofi-aventis, Innogenetics, and Inserm to collaborate on Alzheimer's disease

15-Nov-2006 - Sanofi-aventis, Innogenetics, and Inserm, through its subsidiary called Inserm Transfert, announced the conclusion of a collaborative research agreement in the field of Alzheimer's disease. This collaboration agreement is signed for an initial period of 2 years, with an option for Sanofi-aventis ...

Innogenetics moves into human papillomavirus (HPV) diagnostics in line with its growth strategy

07-Sep-2006 - Innogenetics announced its entry into the field of Human papillomavirus (HPV) diagnostic testing, in line with its diagnostics growth strategy. Infection with HPV genotypes 16 and 18, amongst others, is strongly associated with the development of cervical cancer. These genotypes are also present ...

Innogenetics partners with PamGene to develop its new generation multi parameter diagnostic platform

01-Jun-2004 - Gent (Belgium) and Den Bosch (the Netherlands) - Innogenetics and PamGene International today announced an agreement whereby Innogenetics gains access to PamGene's microarray technology platform for the development of its next generation nucleic acid and protein-based tests. By combining ...

Innogenetics partners with PamGene to develop its new generation multi parameter diagnostic platform

28-May-2004 - Gent (Belgium) and Den Bosch (the Netherlands) - Innogenetics and PamGene International today announced an agreement whereby Innogenetics gains access to PamGene's microarray technology platform for the development of its next generation nucleic acid and protein-based tests. By combining ...